You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.
In a conversation at the Association for Molecular Pathology meeting, the directors touched on topics such as test allocation and staffing and reagent shortages.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
With nearly 7 million COVID-19 cases, the country is expanding near-patient strategies historically deployed for tuberculosis testing for SARS-CoV-2 testing.
The agency provided the update on Wednesday in its weekly virtual town hall and on its FAQ page.
The new method incorporates analysis of the amplification and melt curves and was used to create a single-channel nonaplex test using intercalating dye.
Reported as "nucleic acid amplification test-detectable" units per milliliter, the limits of detection of more than 50 commercial tests differed by 10,000-fold.